Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

Neurology

Volumn 50, Issue 5, 1998, Pages 1266-1272

  Rudick, Richard A ^a   Simonian, N A ^b   Alam, J A ^b   Campion, M ^b   Scaramucci, J O ^b   Jones, W ^b   Coats, M E ^c   Goodkin, D E ^d   Weinstock Guttman, B ^a   Herndon, R M ^e   Mass, M K ^f   Richert, J R ^g   Salazar, A M ^c   Munschauer III, F E ^j   Cookfair, D L ^h   Simon, J H ⁱ   Jacobs, L D ^j  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BIOGEN   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f LEGACY GOOD SAMARITAN HOSPITAL   (United States)

^g GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^h BUFFALO GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j Millard Fillmore Gates Circle Hospital   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BETA1 INTERFERON; BETA1A INTERFERON; NEOPTERIN; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031841745     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.5.1266     Document Type: Article

References (19)

1. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
2. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
3. McKenna RM, Oberg KE. Antibodies to interferon-alpha in treated cancer patients: incidence and significance. J Interferon Cytokine Res 1997;17:141-143.
4. Antonelli G. In vivo development of antibody to interferons: an update to 1996. J Interferon Cytokine Res 1997;17:S39-S46.
5. Figlin RA, Itri LM. Anti-interferon antibodies: a perspective. Semin Hematol 1988;25:9-15.
6. The IFNB Multiple Sclerosis Study Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894.
7. Jacobs LD, Cookfair DL, Rudick RA. A phase III trial of intramuscular recombinant interferon beta for exacerbating-remitting multiple sclerosis: design and conduct of study: baseline characteristics of patients. Multiple Sclerosis 1995;1: 118-135.
8. Kawade Y. Quantitation of neutralization of interferon by antibody. Meth Enzymol 1986;119:558-573.
9. Palleroni AV, Aglione A, Labow M, et al. Interferon immunogenicity: preclinical evaluation of interferon-α 2a. J Interferon Cytokine Res 1997;17:S23-S27.
10. Hochuli E. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 1997;17:S15-S21.
11. Wang C, Eufemi M, Turano C, Giartosio A. Influence of the carbohydrate moiety on the stability of glycoproteins. Biochemistry 1996;35:7299-7307.
12. Keck K. Ir gene control of carrier recognition. III. Cooperative recognition of two or more carrier determinants on insulins of different species. Eur J Immunol 1977;7:811-816.
13. Rosenwasser LJ, Barcinski MA, Schwartz RH, Rosenthal AS. Immune response gene control of determinant selection. II. Genetic control of the murine T lymphocyte proliferative response to insulin. J Immunol 1979;123:471-476.
14. Cohen IR, Talmon J. H-2 genetic control of the response of T lymphocytes to insulins. Priming of nonresponder mice by forbidden variants of specific antigenic determinants. Eur J Immunol 1980;10:284-289.
15. Antonelli G, Giannelli G, Pistello M, et al. Clinical significance of recombinant interferon-alpha 2 neutralizing antibodies in hepatitis patients. J Interferon Res 1994;14:211-213.
16. Von Wussow P, Hehlmann R, Hochhaus T et al. Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia. J Interferon Res 1994;14:217-219.
17. Freund M, Von Wussow P, Diedrich H, et al. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Hematol 1997;72:350-356.
18. Fierlbeck G, Schreiner T, Schaber B, Walser A, Rassner G. Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta. Cancer Immunol Immunother 1994;39:263-268.
19. Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated patients with interferon beta-1b. Ann Neurol 1997;41:669-674.